Maravai LifeSciences Holdings Inc. Class A Common Stock vs Texas Instruments Incorporated — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Texas Instruments Incorporated trades at $278.98 (market cap $262.88B). The key difference: Texas Instruments Incorporated is far larger — about 270.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Texas Instruments Incorporated pays a 2.11% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Texas Instruments Incorporated for 77 Days on average.
| MRVI | TXN | |
|---|---|---|
Market Cap | $972.90M | $262.88B |
Volume | 4,325,710 | 5,600,379 |
Sector | Health | Technology |
52-Week High | $9.00 | $332.35 |
52-Week Low | $2.83 | $153.33 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $1.08B | $269.93B |
Dividend Yield | — | 2.11% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Texas Instruments (TXN) trades at $281.74, down 0.7% on the day, with a neutral technical signal. The stock shows strong profitability with a 31.11% net income margin and 34.97% ROE, though valuation ratios like a P/E of 43.75 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and data center sales growth is a key driver, with news highlighting a 55% year-to-date gain as of September 2026.
The outlook is positive with a consensus price target of $325, implying 15% upside, supported by AI and industrial demand. Risks include high debt-to-asset ratio of 40.61% and semiconductor cycle volatility. Analyst sentiment is mixed but leans bullish with 48% buy ratings.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →